AgomAb Therapeutics NV (AGMB) logo

AgomAb Therapeutics NV (AGMB) stock

Fibrotic therapies , market cap $277M

$5.45
-3.02%

Why is AGMB down?

Down 57% in 3 months, 37% under its 50-day average.

  • Down more than its industry: the 266 other stocks in it fell a median 26% over the same 3 months.

−2Volatility moves 13.8% a day with no recent filing to back it

Tell me next time AGMB moves

Free account, no card. An optional alert when AGMB moves or its score changes.Pro, $1 for a first month. An optional alert when AGMB moves or its score changes.Pro, 7 days free with a card. An optional alert when AGMB moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.

1 more thing pulling AGMB's score down, for Pro members.

Quality Score
2
Below Average
In its industry
#84of 273
Checks firing
2of 14
Trending down
From 52-week high
-69.4%
under its best in a year
See AGMB's 14 chart checksSee AGMB's 14 chart checksSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on AGMB

Key facts on AGMB
Holding it backMoves 13.8% a day with no recent filing behind it
Latest filing6-K, Oct 13 Issued a release: "Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease"

What's next

Sat Feb 6: One year since its IPOListed Feb 6, 2026 at $16.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How AGMB ranks in Biotech

AGMB is #84 of 273 by Quality Score.

How AGMB ranks in Biotech
RankStockQuality Score
84AgomAb Therapeutics NV (AGMB) logoAGMBAgomAb Therapeutics NV2

More in Biotech

AGMB has 2 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on AGMB, and all 14 on every stock.Get in free →See the top 3 →Start Pro

AGMB RSI on Nov 20: 23.0, below its 50-day and 200-day averages

Not scored

RSI 23.0, MACD below signal, below both averages. Not scored.

The deep dive on AGMB

AGMB share count over time

Offerings, shelves, and splits of AGMB, from its filings
From its
filings
Filed
Registered shares for sale (F-1)Jan 16, 2026

AGMB insider trades

3 insiders bought $620K across 18 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyDavid R. Epstein$28KDirectorat $5.57 on Nov 17, filed Nov 19

All 18 insider filings on AGMB from the last six months, for Pro members.

All AGMB insider trades

AGMB's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

About AgomAb Therapeutics NV

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

62 employeesagomab.com

Listed on Nasdaq on Feb 6, 2026, and is 66% below its $16 offer price now. Its IPO filing and first days

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on AGMB and every other stock.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn AGMB's score around: 5 things
  • 2 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayNov 19David R. Epstein bought AGMB$28K at $5.57, filed Nov 19

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: AGMB's Quality Score is 2 (Below Average), #84 of 273 in Biotech. Insiders bought $620K in the last 6 months (Form 4).

What does AGMB's Quality Score say?

AGMB scores 2 today, which Breakaway calls Below Average. It is #84 of 273 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 57% in 3 months, 37% under its 50-⁠day average. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is AGMB's Quality Score?

AGMB scores 2 today, which Breakaway calls Below Average (0 to 5). That is #84 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AGMB's 2.

Are insiders buying AGMB?

3 insiders bought $620K across 18 filings in the last 6 months. No open-⁠market sales on record. The newest is David R. Epstein, Director, who bought $28K on Nov 17. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.